NCT01096004View on ClinicalTrials.gov

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Obesity

Interventions

DRUG

AZD4017

oral suspension, 1200mg, once daily, for 10 days

DRUG

Placebo

Trial Locations (1)

Unknown

Research Site, Gothenburg

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY